October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
March 2017 in “Journal of endourology” The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.
9 citations
,
August 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
June 2020 in “Risk Management and Healthcare Policy” Drinking alcohol 1-2 times a week may reduce urinary symptoms, but drinking more often might increase the risk.
November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.
3 citations
,
February 2021 in “The Journal of Urology” Dutasteride can reduce night-time urination but it doesn't improve sleep quality.
2 citations
,
November 2019 in “Current Geriatrics Reports” Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.
1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
These medications for BPH have known risks and may have new side effects.
2 citations
,
October 2019 in “Minia Journal of Medical Research” UTIs are common in Upper Egypt, with many bacteria resistant to multiple drugs, highlighting the need for better treatment strategies.
22 citations
,
March 2018 in “International Ophthalmology” Taking tamsulosin or finasteride and being older increase the risk of floppy iris during cataract surgery.
15 citations
,
May 1966 in “The Journal of Urology” A woman developed severe bladder inflammation after cancer treatment with Cytoxan.
6 citations
,
November 1998 in “The Journal of Clinical Pharmacology” Finasteride interacts with terazosin, but not doxazosin; caution needed.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
1 citations
,
January 2018 in “Journal of Gynecologic Surgery” Removing both ovaries can treat increased testosterone and related symptoms in postmenopausal women with ovarian hyperthecosis.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” The method accurately and quickly measures silodosin and dutasteride in mixtures.
January 2014 in “Revista del Hospital Juárez de México” Finasteride reduces bleeding during prostate surgery.
January 2003 in “American Journal of Clinical Dermatology” Various drugs caused different skin reactions, including allergic and inflammatory responses.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
386 citations
,
April 2006 in “PubMed” BPH is common in older men and often occurs with other age-related health issues.
November 2011 in “国际泌尿系统杂志” Intraprostatic injection and high-frequency thermotherapy are more effective for treating prostatitis after TURP than antibiotics, tamsulosin, and finasteride.
1 citations
,
October 2017 in “The Journal of Urology” Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.
8 citations
,
September 1997 in “Postgraduate medicine” Older women often have vulva issues due to less estrogen, which can be misdiagnosed and lead to wrong treatments.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
1 citations
,
April 2012 in “Urology” Self-management can help improve symptoms of benign prostatic hyperplasia.
50 citations
,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.